Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
Saved in:
| Title: | Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study. |
|---|---|
| Authors: | Jackson TL; School of Medicine, King's College London, London, United Kingdom., Boyer D; Retina-Vitreous Associates Medical Group, Beverly Hills, California., Brown DM; Blanton Eye Institute, Houston Methodist Hospital, Retina Consultants of Houston, Houston, Texas., Chaudhry N; New England Retina Associates, Guilford, Connecticut., Elman M; Elman Retina Group, Baltimore, Maryland., Liang C; Tyrogenex Inc, Rockville, Maryland., O'Shaughnessy D; Tyrogenex Inc, Rockville, Maryland., Parsons EC; Tyrogenex Inc, Rockville, Maryland., Patel S; Retina Research Institute of Texas, Abilene., Slakter JS; Digital Angiography Reading Center, New York, New York., Rosenfeld PJ; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2017 Jul 01; Vol. 135 (7), pp. 761-767. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2168-6173 |
|---|---|
| DOI: | 10.1001/jamaophthalmol.2017.1571 |
